Drug Profile
Histamine dihydrochloride injection - Immune Pharmaceuticals
Alternative Names: Ceplene; MaxamineLatest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator EpiCept Corporation
- Developer EpiCept Corporation; Immune Pharmaceuticals Inc; Karolinska University Hospital; MegaPharm Ltd; Nordic Group; Sahlgrenska University Hospital
- Class Antiepileptic drugs; Antimigraines; Antineoplastics; Antiparkinsonians; Antipsychotics; Antivirals; Behavioural disorder therapies; Ethylamines; Imidazoles; Neuroprotectants; Small molecules
- Mechanism of Action CYBB protein inhibitors; Immunomodulators; NADPH oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Acute myeloid leukaemia
- Phase I/II Chronic myelomonocytic leukaemia
- No development reported Solid tumours
- Discontinued Alcoholic hepatitis; Hepatitis C; Malignant melanoma; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for preclinical development in Solid-tumours in USA (SC)
- 08 Jan 2020 Histamine dihydrocholoride injection is still in phase I/II trial for Chronic myelomonocytic leukaemia (Combination therapy) in Sweden (EudraCT2014-004874-41)
- 27 Nov 2018 Immune Pharmaceuticals and Vector Therapeutics plans to launch histamine dihydrochloride injection in Europe in 2019